[
  {
    "ts": null,
    "headline": "Veeva Systems (VEEV) Reports Strong Q2 Earnings With US$789 Million Revenue",
    "summary": "Veeva Systems (VEEV) reported a robust second quarter with revenue rising to $789 million and net income increasing to $200 million, marking year-over-year improvements. This financial strength, coupled with the integration of Amazon Web Services and Merck's commitment to Veeva’s services, bolstered investor confidence. The company's inclusion in multiple Russell indices underscored its market position, likely consolidating its share price movement. Although the broader market witnessed a...",
    "url": "https://finnhub.io/api/news?id=25f4605bc6f1d263fcbf3d4efa5482aefea7797645048c9f8b1e1df8a5130ef2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756402842,
      "headline": "Veeva Systems (VEEV) Reports Strong Q2 Earnings With US$789 Million Revenue",
      "id": 136563746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Veeva Systems (VEEV) reported a robust second quarter with revenue rising to $789 million and net income increasing to $200 million, marking year-over-year improvements. This financial strength, coupled with the integration of Amazon Web Services and Merck's commitment to Veeva’s services, bolstered investor confidence. The company's inclusion in multiple Russell indices underscored its market position, likely consolidating its share price movement. Although the broader market witnessed a...",
      "url": "https://finnhub.io/api/news?id=25f4605bc6f1d263fcbf3d4efa5482aefea7797645048c9f8b1e1df8a5130ef2"
    }
  },
  {
    "ts": null,
    "headline": "Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC",
    "summary": "Equillium, Inc. raises $50M to advance EQ504, a novel AhR modulator for ulcerative colitis. Phase 1 trials begin mid-2026. Click for more on EQ stock prospects.",
    "url": "https://finnhub.io/api/news?id=05298a6821a423e89829c846031602b35461c0b7ef1f4908cbbbf3f55e837930",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756402506,
      "headline": "Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC",
      "id": 136564670,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2228863093/image_2228863093.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Equillium, Inc. raises $50M to advance EQ504, a novel AhR modulator for ulcerative colitis. Phase 1 trials begin mid-2026. Click for more on EQ stock prospects.",
      "url": "https://finnhub.io/api/news?id=05298a6821a423e89829c846031602b35461c0b7ef1f4908cbbbf3f55e837930"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=3ef0624804d89280a87f42aa946af99fcd5448494b49d23c6930c97791e1f104",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756398840,
      "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "id": 136571463,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=3ef0624804d89280a87f42aa946af99fcd5448494b49d23c6930c97791e1f104"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?",
    "summary": "Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=354eaf3358c29b0fd80d89620888cdce5a4e2f585181267fbf6682ab16d186fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756395009,
      "headline": "Merck (MRK) Up 2.8% Since Last Earnings Report: Can It Continue?",
      "id": 136563721,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=354eaf3358c29b0fd80d89620888cdce5a4e2f585181267fbf6682ab16d186fe"
    }
  },
  {
    "ts": null,
    "headline": "MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate",
    "summary": "Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.",
    "url": "https://finnhub.io/api/news?id=119d39afa8c3e6bfc439e7a1c59565c9920d3b3ea70ce6bcb3eca2b1e6df90da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756393980,
      "headline": "MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate",
      "id": 136563748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.",
      "url": "https://finnhub.io/api/news?id=119d39afa8c3e6bfc439e7a1c59565c9920d3b3ea70ce6bcb3eca2b1e6df90da"
    }
  },
  {
    "ts": null,
    "headline": "Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?",
    "summary": "Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.",
    "url": "https://finnhub.io/api/news?id=a72c3586afaa7ece6e70f2b2971d4a5c05086bda0c20505f68b074db1b0e3903",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756387320,
      "headline": "Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?",
      "id": 136560799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.",
      "url": "https://finnhub.io/api/news?id=a72c3586afaa7ece6e70f2b2971d4a5c05086bda0c20505f68b074db1b0e3903"
    }
  },
  {
    "ts": null,
    "headline": "Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?",
    "summary": "Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.",
    "url": "https://finnhub.io/api/news?id=7cf6619cacd0c6ff6f17e8ab088b71c176aa0f33b466097d8e5bd9320569107f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756387260,
      "headline": "Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?",
      "id": 136560852,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck halts Gardasil shipments in China after weak demand hurts sales, with declines also seen in Japan.",
      "url": "https://finnhub.io/api/news?id=7cf6619cacd0c6ff6f17e8ab088b71c176aa0f33b466097d8e5bd9320569107f"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Participate in the 2025 Wells Fargo Healthcare Conference",
    "summary": "RAHWAY, N.J., August 28, 2025--Merck to Participate in the 2025 Wells Fargo Healthcare Conference",
    "url": "https://finnhub.io/api/news?id=c0797b94a2994d382d36bd168e01eaaba7065e84cd7a652a09f583220384af4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756377900,
      "headline": "Merck to Participate in the 2025 Wells Fargo Healthcare Conference",
      "id": 136557863,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., August 28, 2025--Merck to Participate in the 2025 Wells Fargo Healthcare Conference",
      "url": "https://finnhub.io/api/news?id=c0797b94a2994d382d36bd168e01eaaba7065e84cd7a652a09f583220384af4c"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances",
    "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now.Merck & Co., Inc. is one of them. Merck & Co., Inc. (NYSE:MRK) tops our list for being one of the best cancer stocks. It is a global pharmaceutical leader with a strong oncology portfolio led by KEYTRUDA (pembrolizumab), approved for 42 indications across 18 tumor […]",
    "url": "https://finnhub.io/api/news?id=bed02e802e74beed8775a6817b902e1d59d67f7b8feecefbc69dea43ec49055a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756371758,
      "headline": "Merck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances",
      "id": 136557864,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now.Merck & Co., Inc. is one of them. Merck & Co., Inc. (NYSE:MRK) tops our list for being one of the best cancer stocks. It is a global pharmaceutical leader with a strong oncology portfolio led by KEYTRUDA (pembrolizumab), approved for 42 indications across 18 tumor […]",
      "url": "https://finnhub.io/api/news?id=bed02e802e74beed8775a6817b902e1d59d67f7b8feecefbc69dea43ec49055a"
    }
  },
  {
    "ts": null,
    "headline": "Moderna, Inc. (MRNA) Expands Into Oncology with Pan-Tumor Vaccine",
    "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Moderna, Inc. stands fifth among them. Moderna, Inc. (NASDAQ:MRNA) stands fifth among the best cancer stocks. It is best known for its mRNA COVID-19 vaccine and is expanding into oncology with a focus on personalized cancer immunotherapies. The company’s strategy centers on using mRNA technology to […]",
    "url": "https://finnhub.io/api/news?id=305f45342dd4850f39d4fec08d2a59e003a3077c980c9bd43b1ac7d1bff44f68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756371406,
      "headline": "Moderna, Inc. (MRNA) Expands Into Oncology with Pan-Tumor Vaccine",
      "id": 136557865,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Moderna, Inc. stands fifth among them. Moderna, Inc. (NASDAQ:MRNA) stands fifth among the best cancer stocks. It is best known for its mRNA COVID-19 vaccine and is expanding into oncology with a focus on personalized cancer immunotherapies. The company’s strategy centers on using mRNA technology to […]",
      "url": "https://finnhub.io/api/news?id=305f45342dd4850f39d4fec08d2a59e003a3077c980c9bd43b1ac7d1bff44f68"
    }
  }
]